2-(2-Aminoethyl)-quinoline (D-1997): A novel agonist at craniovascular 5-HT1 receptors relevant to migraine therapy

CNS Drug Reviews

Volumn 6, Issue 4, 2000, Pages 267-277

  Terrón, José A ^a,b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

D 1997; Migraine; Quinoline derivatives; Serotonin; Vascular 5 HT1B 1D receptors; Vasoconstriction

Indexed keywords

2 (2 AMINOETHYL)QUINOLINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 5 CARBAMOYLTRYPTAMINE; ANTIMIGRAINE AGENT; D 1997; N BETA ACETOXYETHYLQUIPAZINE; N BETA HYDROXYETHYLQUIPAZINE; N METHYLQUIPAZINE; QUINOLINE DERIVATIVE; QUIPAZINE; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; CAROTID ARTERY; CONCENTRATION RESPONSE; DOG; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; MIGRAINE; NONHUMAN; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; VASOCONSTRICTION;

EID: 0034442315     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2000.tb00152.x     Document Type: Review

References (47)

1. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 1993;90:408-412.
2. Bouchelet I, Cohen Z, Case B, Séguéla P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996;50:219-223.
3. 1F receptor agonists in human and bovine cerebral arteries: Similarity with human coronary artery. Br J Pharmacol 2000;129:501-508.
4. 1A receptor agonists and subtypes of alpha-1 adrenoceptors on rabbit aorta. Eur J Pharmacol 1993;241:141-148.
5. Castro ME, Romon T, Castillo MJ, del Olmo E, Pazos A, del Arco C. Identification and characterization of a new serotonergic recognition site with high affinity for 5-carboxamidotryptamine in mammalian brain. J Neurochem 1997;69:2123-2131.
6. 2 receptors mediating contraction in vascular smooth muscle. J Pharmacol Exp Ther 1982;218:421-425.
7. Cohen ML, Schenck K. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: Lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther 1999;290:935-39.
8. 1,-Iike receptor agonist. Br J Pharmacol 1989;96:379-387.
9. 1B/1D and novel receptors. Br J Pharmacol 1998;123:1561-1570.
10. 1D (BRL15572) reB ceptor antagonists. Eur J Pharmacol 1998;362:69-72.
11. 1-like receptors. Br J Pharmacol 1991;104:183-189.
12. 7 receptor: Orphan found. Trends Pharmacol Sci 1997;18:104-107.
13. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993;14:129-133.
14. 3 serotonin receptors: Results of a structure-affinity study. Eur J Pharmacol 1989;168:387-392.
15. 1B receptors causes hypothermia in the guinea pig. Eur J Pharmacol 1997;31:169-174.
16. 1D receptor subtypes. Trends Pharmacol Sci 1996;17:103-105.
17. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
18. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-446.
19. 1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988;94:1123-1132.
20. Humphrey PPA, Apperley E, Feniuk W, Perren MJ. A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, Bevan P, eds. Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications. Dordrecht: Kluwer Academic Publishers, 1990;416-431.
21. 1B immunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs. Cephalalgia 1997;17:833-842.
22. 2A receptors in cardiovascular regulation in anaesthetized rats. Br J Pharmacol 1999;128:530-542.
23. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-311.
24. Pauwels PJ, John GW. Present and future of 5-HT receptor agonists as antimigraine drugs. Clin Neuropharmacol 1999;22:123-136.
25. 1D subtype. Br J Pharmacol 1991;102:191-197.
26. Saxena PR. The effects of antimigraine drugs on the vascular responses by-5-hydroxytryptamine and related biogenic substances on the external carotid bed of dogs: Possible pharmacological implications to their antimigraine action. Headache 1972;12:44-54.
27. Saxena PR. Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Eur J Pharmacol 1974;27:99-105.
28. Saxena PR, de Vlaam-Schluter GM. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine studies in an experimental model for migraine. Headache 1974;13:142-163.
29. 1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989;10:200-204.
30. Saxena PR, Tfelt-Hansen P. Sumatriptan. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press, 1993:329-341.
31. 1-like" receptors. Naunyn Schmiedebergs Arch Pharmacol 1986;333:98-204.
32. 1D receptor antagonist. Behav Brain Res 1996;73:157-161.
33. The Subcutaneos Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-321.
34. 7 receptor subtype. Br J Pharmacol 1990;118:1421-1428.
35. 1-like receptor mediating contraction in the canine coronary artery. Eur J Pharmacol 1996;300:109-112.
36. 7 receptors in the long-lasting hypotensive response induced by 5-hydroxytryptamine in the rat. Br J Pharmacol 1997;121:563-571.
37. 7 receptor: A target for novel therapeutic avenues? Drugs 1998;1:302-310.
38. 7 receptor mediating smooth muscle relaxation in canine cerebral arteries. Br J Pharmacol 1999;127:609-616.
39. 1-like receptors in the canine basilar artery. Arch Int Pharmacodyn Ther 1994;237:56-68.
40. 1-like receptors. Proc West Pharmacol Soc 1994;37:93-94.
41. Terrón JA, Hong E, Villalón CM. Pharmacological screening of some quinoline derivatives in canine vascular smooth muscle. Arch Med Res 1994;25:435-440.
42. 1D receptor agonists in the rabbit isolated saphenous vein. Br J Pharmacol 1996;119:35-42.
43. 1B receptor-mediated contractions in human temporal artery: Evidence from selective antagonists and 5-HT receptor mRNA expression. Br J Pharmacol 1998;124:1345-1354.
44. Villalón CM, Ramírez-San JE, Castillo C, Castillo E, López-Mun̄oz FJ, Terrón JA. Pharmacological profile of the receptors that mediate external carotid vasoconstriction by 5-HT in vagosympathectomized dogs. Br J Pharmacol 1995;116:2778-2784.
45. 1-like receptor-mediated external carotid vasoconstriction in vagosympathectomized dogs. Ann NY Acad Sci 1997;812:207-208.
46. 7 receptor. Br J Pharmacol 1997;120:1319-1327.
47. Villalón CM, López-Mun̄oz FJ, Perusquía M, Terrón JA. External carotid effects of 2-(2-aminoethyl)-quinoline (D-1997) in vagosympathectomized dogs. Eur J Pharmacol 1998;356:15-23.